<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722436</url>
  </required_header>
  <id_info>
    <org_study_id>PRO07120134</org_study_id>
    <nct_id>NCT00722436</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for Craniofacial Surgery</brief_title>
  <official_title>Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, blinded, prospective study that will investigate the potential benefit
      of tranexamic acid to reduce the intraoperative bleeding and blood transfusions in pediatric
      patients undergoing craniofacial surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical procedures for the correction of craniofacial deformities result in unavoidable and
      significant blood loss in small children and infants. Patients may experience blood losses
      that exceed one to two blood volumes. In an effort to reduce our transfusion requirements, we
      have introduced tranexamic acid into our practice. However, the benefit of tranexamic acid in
      pediatric craniofacial surgery has not yet been reported. We hypothesize that the
      intraoperative use of tranexamic acid in pediatric patients presenting for craniofacial
      reconstructions will reduce blood loss and allogeneic transfusion requirements.

      This is a randomized, blinded, prospective study that will investigate the potential benefit
      of tranexamic acid to reduce the intraoperative bleeding and blood transfusions in pediatric
      patients undergoing craniofacial surgeries. An initial dose of 100 mg/kg tranexamic acid
      (Cyclokapron 100mg/ml) or an equal volume of a placebo will be administered over 15 minutes
      after the induction of anesthesia and before the skin incision. A maintenance infusion of 10
      mg/kg/hr of tranexamic acid or equal volume of a placebo will be started upon completion of
      the initial dose and will be continued until skin closure. The primary outcome will include
      the reduction in the total volume of allogeneic erythrocytes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study dose changed based on recent publications
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Volume (ml/kg) of Allogeneic Blood Exposure.</measure>
    <time_frame>intraoperative and postoperative (24 hr)</time_frame>
    <description>This is the blood administered during surgery. The blood comes form the blood bank. It is not cell salvage blood. The volume was normalized by weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients That Remained Transfusion Free</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Tranexamic Acid on Prothrombin Time (PT), Partial Thromboplastin Time (PTT) at Three Time Points (Baseline, After Osteotomies, and Immediately After Procedure).</measure>
    <time_frame>(baseline, after osteotomies, and immediately after procedure)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>baseline, after osteotomies, immediately after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Craniosynostosis</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline was administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>100 mg/kg load, then 10 mg/kg/hr</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The inclusion of the patients will depend on the following criteria:

          1. All pediatric patients scheduled for primary or secondary repair of craniosynostosis
             with a frontal orbital advancement, or cranial vault reconstruction.

          2. Patients will be between the ages of 6 months and 18 years old.

          3. They will be &gt; than 5 kg.

          4. All subjects being evaluated in the Craniofacial Clinic for primary or secondary
             repair of craniosynostosis will potentially be included in the study. Prior to
             inclusion in the study potential participants will be screened by history and
             laboratory data. The laboratory data will include a complete blood count, PT, PTT,
             type and cross, factor V leiden, anticardiolipin antibody, and lupus anticoagulant.
             The history will be obtained from the parents or current care takers. The medical
             records may be reviewed if there is a need for clarification.

        Exclusion Criteria:

        Patients that will be excluded from the study include the following:

          1. Familial or personal coagulopathy risk-factor V leiden, anticardiolipin antibody, and
             lupus anticoagulant

          2. Abnormal PT, PTT, Platelet count. or closing time. All patients presenting for
             craniofacial surgery have preoperative blood work performed which includes a type and
             screen, HCT, PLT, PT, PTT, and closing time. Patients who have abnormalities detected
             in their coagulation profile proceed on to a complete hematologic evaluation that
             includes an evaluation for Von Willebrand's Disease.

          3. History of thrombotic episodes in the patient

          4. Renal failure or hepatic failure.

          5. Infants less than 5 kg

          6. Age &lt; 6 months or &gt; 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Neilipovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WM. A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesth Analg. 2001 Jul;93(1):82-7.</citation>
    <PMID>11429344</PMID>
  </reference>
  <reference>
    <citation>Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology. 2005 Apr;102(4):727-32.</citation>
    <PMID>15791100</PMID>
  </reference>
  <reference>
    <citation>Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001;(1):CD001886. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD001886.</citation>
    <PMID>11279735</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2017</results_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Franklyn Cladis</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>antifibrinolytic, tranexamic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniosynostoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We stopped the study early because emerging data came out that demonstrated benefit with significantly lower doses than our study. We were compelled to stop enrolling.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Tranexamic acid: 100 mg/kg load, then 10 mg/kg/hr
Patients are randomized to TXA or saline. This group is the TXA group.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline
saline: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Tranexamic acid: 100 mg/kg load, then 10 mg/kg/hr
Patients are randomized to TXA or saline. This group is the TXA group.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline
saline: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Volume (ml/kg) of Allogeneic Blood Exposure.</title>
        <description>This is the blood administered during surgery. The blood comes form the blood bank. It is not cell salvage blood. The volume was normalized by weight.</description>
        <time_frame>intraoperative and postoperative (24 hr)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Tranexamic acid: 100 mg/kg load, then 10 mg/kg/hr
Patients are randomized to TXA or saline. This group is the TXA group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline
saline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume (ml/kg) of Allogeneic Blood Exposure.</title>
          <description>This is the blood administered during surgery. The blood comes form the blood bank. It is not cell salvage blood. The volume was normalized by weight.</description>
          <units>ml/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="13.9"/>
                    <measurement group_id="O2" value="17.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients That Remained Transfusion Free</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Tranexamic acid: 100 mg/kg load, then 10 mg/kg/hr
Patients are randomized to TXA or saline. This group is the TXA group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline
saline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Remained Transfusion Free</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Tranexamic Acid on Prothrombin Time (PT), Partial Thromboplastin Time (PTT) at Three Time Points (Baseline, After Osteotomies, and Immediately After Procedure).</title>
        <time_frame>(baseline, after osteotomies, and immediately after procedure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Tranexamic acid: 100 mg/kg load, then 10 mg/kg/hr
Patients are randomized to TXA or saline. This group is the TXA group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline
saline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Tranexamic Acid on Prothrombin Time (PT), Partial Thromboplastin Time (PTT) at Three Time Points (Baseline, After Osteotomies, and Immediately After Procedure).</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT -baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="0.84"/>
                    <measurement group_id="O2" value="13.8" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-after osteotomies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="3.93"/>
                    <measurement group_id="O2" value="16.1" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-immediately after surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="1.18"/>
                    <measurement group_id="O2" value="17" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTT -baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="2.92"/>
                    <measurement group_id="O2" value="32.9" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTT-after osteotomies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" spread="9.75"/>
                    <measurement group_id="O2" value="34.6" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTT-immediately after surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="3.5"/>
                    <measurement group_id="O2" value="34.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelets</title>
        <time_frame>baseline, after osteotomies, immediately after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Tranexamic acid: 100 mg/kg load, then 10 mg/kg/hr
Patients are randomized to TXA or saline. This group is the TXA group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline
saline: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Platelets</title>
          <units>10^9 platelets/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>platelets-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301" spread="109"/>
                    <measurement group_id="O2" value="364" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>platelets-after osteotomies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253" spread="101"/>
                    <measurement group_id="O2" value="300" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>platelets-immediately after surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" spread="89"/>
                    <measurement group_id="O2" value="231" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic acid (100 mg/kg load, 10 mg/kg/hr)
Tranexamic acid: 100 mg/kg load, then 10 mg/kg/hr
Patients are randomized to TXA or saline. This group is the TXA group.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline
saline: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated because two studies published during the trial demonstrated efficacy of tranexamic acid at a lower dose.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Franklyn Cladis</name_or_title>
      <organization>The Childrens Hospital of Pittsburgh of UPMC</organization>
      <phone>412-692-5260</phone>
      <email>cladfp@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

